Cost-Consequence Analysis of Apixaban Versus Rivaroxaban for Managing Patients with Venous Thromboembolism in Saudi Arabia

Cost-Consequence Analysis of Apixaban Versus Rivaroxaban for Managing Patients with Venous Thromboembolism in Saudi Arabia

Background and Objective Direct oral anticoagulants (DOACs) have been proven to be cost-effective for treating various conditions, including venous thromboembolism (VTE). Nevertheless, there are no studies assessing the cost-effectiveness of DOACs for VTE treatment in Saudi Arabia using real-world d...

Full description

Saved in:
Bibliographic Details
Main Authors: Abdulaali R. Almutairi PhD, Yazed Alruthia PhD, Majed S. Alyami PharmD, Omar A. Alshaya PharmD, Taif Z. Alanazi PharmD, Sarah I. Al Daghreer PharmD, Ghazwa B. Korayem PharmD, Sarah A. Alrasheed PharmD, Reema A. Alorf PharmD, Omar A. Almohammed PhD
Format: Article
Language:English
Published: SAGE Publishing 2025-02-01
Series:Clinical and Applied Thrombosis/Hemostasis
Online Access:https://doi.org/10.1177/10760296251318705
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1177/10760296251318705

Similar Items